Close Menu
  • Home
  • News
  • Business
  • Technology
  • Lifestyle
  • Travel
What's Hot

2026 GMC Terrain Arrives in Middle East with Bold Redesign

July 6, 2025

DLSS 4 Boosts Mecha BREAK, Diablo IV & NTE Performance

July 6, 2025

Emirates Group Spotlights Sustainability at Showcase

July 6, 2025
  • About us
  • Editorial policy
  • Contact
X (Twitter)
Abu Dhabi Week
  • Home
  • News
  • Business
  • Technology
  • Lifestyle
  • Travel
Subscribe
Abu Dhabi Week
Home » AUB Leads Breakthrough in Thalassemia Treatment
News

AUB Leads Breakthrough in Thalassemia Treatment

Sam AllcockBy Sam AllcockJuly 6, 2025No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
Share
Facebook Twitter LinkedIn Pinterest Email

A global phase 3 clinical trial led by the American University of Beirut (AUB) and Lebanon’s Chronic Care Center has shown that mitapivat, an oral therapy, significantly improves outcomes in non-transfusion-dependent thalassemia (NTDT) — marking a historic shift in the treatment of the lifelong blood disorder.

The findings, published in The Lancet, one of the world’s leading medical journals, demonstrate the first successful results of an oral, disease-modifying therapy for both alpha- and beta-thalassemia forms of NTDT. The study was led by Dr. Ali Taher, professor of medicine at AUB and global principal investigator of the trial.

“This publication is more than a scientific milestone,” said Dr. Taher. “It’s proof that Lebanon, even in its hardest times, can lead groundbreaking medical advances that change global standards of care.”

NTDT is a hereditary condition in which patients suffer from chronic anemia without requiring regular blood transfusions. Despite the absence of frequent transfusions, patients often experience serious complications such as iron overload, fatigue, and reduced quality of life. Therapeutic options until now have remained extremely limited.

Mitapivat, developed as an oral treatment to enhance red blood cell energy metabolism, is currently under review by the U.S. Food and Drug Administration (FDA) for potential marketing authorization. If approved, it would become the first FDA-authorised oral therapy for NTDT patients globally.

The phase 3 trial, formally titled “Phase 3 trial of mitapivat in non-transfusion-dependent alpha- or beta-thalassemia,” met all primary and secondary endpoints, showing statistically and clinically significant increases in hemoglobin levels, with a favorable safety profile.

The study builds upon over a decade of research led by AUB. Dr. Taher previously spearheaded the THALASSA trial, which led to advances in iron chelation therapy, and the BEYOND trial, resulting in the approval of luspatercept for beta-thalassemia. Both have since shaped international treatment standards.

“This work is a continuation of our mission to redefine how thalassemia is treated,” Dr. Taher noted. “Our focus has always been on the patients who live with this disease every day, often without sufficient treatment.”

Beyond its scientific contributions, the study is a testament to Lebanon’s ability to contribute meaningfully to global healthcare innovation—even amid economic and political instability.

The trial’s success positions AUB and Lebanon at the forefront of global hematology research, reinforcing the university’s reputation for academic excellence and clinical leadership.

It also reflects the unwavering resilience of Lebanon’s scientific community. As Dr. Taher concludes: “Despite immense challenges, we continue to strive, research, and deliver solutions that have global impact.”

With FDA approval pending, thousands of patients across the world may soon benefit from a new standard of care, bringing renewed hope to families affected by this chronic genetic condition.

Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
Previous ArticleGU-Q Course Spotlights Voices of Gulf Women
Next Article Maserati GT2 Expands to Global Racing Circuits
Sam Allcock
  • Website

Sam Allcock is a seasoned media professional and content strategist with a passion for storytelling across digital platforms. As a contributor to Abu Dhabi Week, Sam brings a sharp editorial eye and a deep appreciation for the culture, innovation, and lifestyle that define the UAE capital. With over a decade of experience in journalism and public relations, he covers everything from local events and business trends to travel, dining, and community highlights. When he's not writing, Sam is exploring the hidden gems of Abu Dhabi, always on the lookout for the next story worth sharing.

Related Posts

Emirates Group Spotlights Sustainability at Showcase

July 6, 2025

Wizz Air Tops Global Airline Emissions Efficiency Rankings

July 6, 2025

du Wins Big for Sustainability at FM Awards 2025

July 5, 2025

Dubai South Earns Great Place to Work Certification

July 5, 2025
Leave A Reply Cancel Reply

Don't Miss
Technology

2026 GMC Terrain Arrives in Middle East with Bold Redesign

By Sam AllcockJuly 6, 20250

GMC Middle East has officially launched the next-generation 2026 GMC Terrain, marking a striking evolution…

DLSS 4 Boosts Mecha BREAK, Diablo IV & NTE Performance

July 6, 2025

Emirates Group Spotlights Sustainability at Showcase

July 6, 2025

Ooredoo Launches Fifth Vanity Number Auction

July 6, 2025
About Us
About Us

Abu Dhabi Week delivers the latest business news, insights, and updates from the heart of the UAE.

Connect with us: advertising@abudhabiweek.ae | editor@abudhabiweek.ae.

Our Picks
New Comments
    X (Twitter)
    © 2025 Abu Dhabi Week

    Type above and press Enter to search. Press Esc to cancel.